| Literature DB >> 25196937 |
Priyanka Sahariah1, Vivek S Gaware2, Ramona Lieder3, Sigríður Jónsdóttir4, Martha Á Hjálmarsdóttir5, Olafur E Sigurjonsson6, Már Másson7.
Abstract
A series of water-soluble cationicEntities:
Mesh:
Substances:
Year: 2014 PMID: 25196937 PMCID: PMC4145335 DOI: 10.3390/md12084635
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Scheme 1Synthesis of final N-(2-(N,N,N-trimethylammoniumyl)acetyl)-chitosan chloride (TMA-CS) (6–) and N-(2-(1-pyridiniumyl)acetyl)-chitosan chloride (PyA-CS)(8–) derivatives. Reactions and conditions: (a) MeSO3H/H2O (1:1), 10 °C, 1 h (90%); (b) tert-butyl-dimethylsilyl chloride (TBDMSCl), imidazole, DMSO, 25 °C, 24 h (96%); (c) bromoacetyl bromide, Et3N, CH2Cl2, −20 °C, 1 h (92%); (d) Me3N (31%–35% wt in EtOH, 4.2 M),_CH2Cl2,_25 °C, 12 h; (e) pyridine, 25 °C, 24 h; (f) conc HCl/MeOH, 25 °C, 24 h, ion exchanged by (8%) acqueos NaCl (w/v), 1 h, dialysed against de-ionised water, 48h.
Figure 11H NMR spectra overlay of the main compounds and final C-2 spacer quaternary derivatives of the representative chitosan material (CS-i, 7%_DA): (A) chitosan mesylate salts (Mes-CS), 2; (B) diTBDMS-CS, 3; (C) N-(bromoacetyl)-3,6-di-O-TBDMS-chitosan (BrA-diTBDMS-CS), 4; (D) TMA-CS, 6; (E) PyA-CS, 8.
Figure 2FT-IR spectra overlay of the main compounds and final C-2 spacer quaternary derivatives of the representative chitosan material (CS-i, 7%_DA): (A) Mes-CS, 2; (B) diTBDMS-CS, 3; (C) BrA-diTBDMS-CS, 4; (D) TMA-CS, 6; (E) PyA-CS, 8.
Figure 3Possible intramolecular cyclization of C-3, C-4 and C-5 spacer compounds based on the findings of Stirling et al. [43].
Scheme 2Synthesis of final N-(6-(N,N,N-trimethylammoniumyl)hexanoyl)-chitosan chloride (TMHA-CS) (11–) and PyHA-CS (13–) derivatives. Reactions and conditions: (a) 6-bromohexanoyl chloride, Et3N, CH2Cl2, −20 °C, 1 h (69%); (b) Me3N (31%–35% wt in EtOH, 4.2 M), KI, CH2Cl2, 25 °C, 48 h; (c) pyridine, KI, 25 °C, 48 h; (d) conc HCl/MeOH, 25 °C, 24 h, ion exchange by (5%–8%) NaCl (aqueous) (w/v), 1 h, dialysed against de-ionised water, 48 h.
Figure 41H NMR spectra overlay of the main compounds and final C-6 spacer quaternary derivatives of the representative chitosan material (CS-iv, 19%DA): (A) Mes-CS (2); (B) diTBDMS-CS (3); (C) BrHA-diTBDMS-CS (9); (D) TMHA-CS (11); (E) PyHA-CS (13).
Figure 5FT-IR overlay of the main compounds and final quaternary derivatives of the representative chitosan material (CS-iv, 19%_DA): (A) Mes-CS (2); (B) diTBDMS-CS (3); (C) BrHA-diTBDMS-CS (9); (D) TMHA-CS (11); (E) PyHA-CS (13).
Scheme 3Synthetic route for N,N,N-trimethyl chitosan chloride (TMC) derivatives (15–). Reactions and conditions: (a) CH3I, Cs2CO3, NMP, 45–50 °C; (b) TBAF (1 M), NMP, 50 °C.
Physical properties of chitosan derivatives.
| Parent Chitosan Material | DA (%) | Chitosan (1i–v) | Mes-CS (2i–v) | TMA-CS (6i–v) | PyA-CS (8i–v) | TMHA-CS (11i–v) | PyHA-CS (13i–v) | TMC (15i–v) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mw | (PDI) | Mw | (PDI) | Mw | (PDI) | Mw | (PDI) | Mw | (PDI) | Mw | (PDI) | Mw | (PDI) | ||
| CS-i | 7 | 235 | (2.8) | 24.6 | (1.6) | 23.8 | (2.1) | 18.8 | (1.8) | 17.3 | (1.6) | 12.9 | (1.5) | 18.7 | (1.5) |
| CS-ii | 6 | 294 | (2.3) | 20.8 | (1.9) | 17.1 | (1.8) | 17.3 | (2.0) | 15.1 | (1.5) | 9.8 | (1.3) | 15.3 | (1.4) |
| CS-iii | 17.3 | 225 | (2.6) | 19.1 | (1.6) | 16.4 | (1.6) | 12.2 | (1.9) | 13.1 | (1.4) | - | - | 13.2 | (1.4) |
| CS-iv | 19 | 308 | (2.6) | 21.4 | (2.4) | 16.7 | (1.6) | 14.6 | (1.8) | 14.2 | (1.8) | 15.8 | (1.1) | 19.8 | (1.6) |
| CS-v | 34.2 | 180 | (2.9) | 19.5 | (1.5) | 18.9 | (1.7) | 10.8 | (1.4) | 7.4 | (1.4) | - | - | 16.5 | (1.5) |
The average molecular weight (Mw) is in kDa, and the polydispersity index is abbreviated as (PDI). DA = degree of acetylation.
Antibacterial activity, hemolytic activity and cytotoxicity of the quaternary chitosan derivatives.
| Compounds | Structure | HC50 (μg/mL) | Selectivity (HC50/MIC) | EC50 (μg/mL) | |||||
|---|---|---|---|---|---|---|---|---|---|
| MIC (μg/mL) | MLC (μg/mL) | MIC (μg/mL) | MLC (μg/mL) | ||||||
| TMC ( | 8 | 64 | 256 | 256 | 6114 | 764 | 47.7 | 40 | |
| TMC ( | 32 | 32 | 64 | 64 | 6114 | 191 | 95.5 | - | |
| TMC ( | 4 | 4 | 64 | 64 | 6114 | 1528 | 95.5 | - | |
| TMC ( | 8 | 8 | 256 | 256 | 3072 | 764 | 47.7 | 10 | |
| TMC ( | 32 | 32 | 256 | 1024 | 640 | 191 | - | - | |
| TMA-CS ( | 8 | 8 | 16,384 | ≥32,768 | ≥32,768 | ≥4096 | ≥2 | 26 | |
| TMA-CS ( | 8 | 8 | 16,384 | 16,384 | ≥32,768 | ≥4096 | ≥2 | - | |
| TMA-CS ( | 32 | 32 | 16,384 | 16,384 | ≥32,768 | ≥1024 | ≥2 | - | |
| TMA-CS ( | 32 | 32 | ≥32,768 | ≥32,768 | ≥32,768 | ≥1024 | - | 66 | |
| TMA-CS ( | 128 | 128 | ≥32,768 | ≥32,768 | ≥32,768 | ≥256 | - | - | |
| PyA-CS ( | 8 | 1024 | 16,384 | 16,384 | ≥32,768 | ≥8192 | ≥2 | 38 | |
| PyA-CS ( | 8 | 512 | 8192 | 8192 | ≥32,768 | ≥8192 | ≥4 | - | |
| PyA-CS ( | 1024 | 1024 | 16,384 | 16,384 | ≥32,768 | ≥8 | ≥2 | - | |
| PyA-CS ( | 512 | 1024 | 16,384 | 16,384 | ≥32,768 | ≥16 | ≥2 | 12 | |
| PyA-CS ( | 512 | 512 | 128 | 8192 | ≥32,768 | ≥64 | ≥256 | - | |
| TMHA-CS ( | 1024 | 2048 | 256 | ≥32,768 | ≥32,768 | ≥32 | ≥128 | 644 | |
| TMHA-CS ( | 2048 | 2048 | 512 | 16,384 | ≥32,768 | ≥16 | ≥64 | - | |
| TMHA-CS ( | 1024 | 2048 | 128 | ≥32,768 | ≥32,768 | ≥4 | ≥256 | - | |
| TMHA-CS ( | 2048 | 4096 | 512 | ≥32,768 | ≥32,768 | ≥8 | ≥64 | 108 | |
| TMHA-CS ( | 1024 | 4096 | 1024 | ≥32,768 | ≥32,768 | ≥32 | ≥32 | - | |
| PyHA-CS ( | 4096 | 4096 | ≥32,768 | ≥32,768 | ≥32,768 | ≥8 | - | 4 | |
| PyHA-CS ( | 2048 | 2048 | ≥32,768 | ≥32,768 | ≥32,768 | ≥32 | - | - | |
| PyHA-CS ( | 8192 | 8192 | ≥32,768 | ≥32,768 | ≥32,768 | ≥4 | - | - | |
| PyHA-CS ( | 2048 | 2048 | 16,384 | 16,384 | ≥32,768 | ≥16 | ≥2 | 18 | |
| PyHA-CS ( | 2048 | 2048 | ≥32,768 | ≥32,768 | ≥32,768 | ≥16 | - | - | |
The antibacterial tests was done according the Clinical and Laboratory Standards Institute (CLSI) protocol (see Section 3.4.1). According to this procedure, a single dilution series was done for each compound, and gentamycin was used as a positive control. A difference of 1–2 dilutions is therefore not considered significant. The hemolysis measurements were also done in singlets for each concentration. The cytotoxicity measurements were carried out in triplicate, and the standard deviation varied from 10% to 22%.
Figure 6Variation in the antibacterial activity of chitosan with different DA against (A) S. aureus and (B) E. coli.
Figure 7Light microscopic images of RBC. (A) RBC suspended in TBS; (B) RBC treated with Compound 15 (512 μg/mL); (C) RBC treated with Compound 15 (8192 μg/mL); and (D) RBC treated with 1% (v/v) Triton-X100.